FDA grants Fast Track designation to Corthera's relaxin for treating acute heart failure

Links shared publicly online about this topic.

1,705
total visits

FDA grants Fast Track designation to Corthera's relaxin for treating acute heart failure

Corthera Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to relaxin, the company's investigational drug for the treatment of acute heart failure (AHF). The Fast Track program facilitates the development and expedites the review of new drugs intended to treat serious or life-threatening conditions and that demonstrate the potential to address unmet medical needs.

View full resource at news-medical.net

Tags: Heart, Heart Disease, Heart Failure, Health Insurance, Medicare, FDA, News